e-ESO Podcasts

Expert: Astrid Pavlovsky , Clinical Research Center - FUNDALEU, Buenos Aires, Argentina 1 - Why do chemorefractory patients respond to checkpoint inhibitors? 2 - Can you comment on the design and results of the KEYNOTE 204 for patients with RR HL? 3 - What do you think are the future challenges and therapeutic options in this group of patients?

Expert: Maria Alice Franzoi , Jules Bordet Institute, Brussels, Belgium Questions: 1 - Can you describe a visceral crisis to us? 2 - What about a work up and evaluation of liver disfunction in breast cancer? 3 - Can you explain how to manage liver disfunction with supportive care?  4 - Which agents should we use and with what dosage in the role of systemic treatment in liver disfunction?

Experts:  Giancarlo Pruneri , National Cancer Institute, Milan, Italy Catarina Eloy , Ipatimup Institute, Porto, Portugal

Expert: Stephan Rauh , Hospital Center Emile Mayrisch, Esch-sur-Alzette, Luxembourg Questions: 1- What would be your approach to patients for whom anticoagulation is of uncertain benefit, for example with active malignant disease in pelvis creating continuous venous compression and conditions for recurrent or progressive thrombosis? 2- In a cancer patient with creatinine clearance bellow 30 mcmol/...

Expert: Pierfrancesco Franco, University of Eastern Piedmont, Novara, Italy Questions: 1- Why job is so important for people’ s life? 2- What is burn-out and what are its main characteristics? 3- What are the causes of burnout and decreased professional well-being? 4- Why burn-out is a crucial issue for healthcare providers, particularly in the field of oncology, and what are its consequences? 5-...

Expert: Agata Rembielak, The Christie NHS Foundation Trust, Manchester, United Kingdom Questions: 1- Should we all worry about skin cancer and how common is it? 2- What are the recent developments in skin radiotherapy? 3- How successful is skin radiotherapy and which patients should consider this option? 4- Is there a role of systemic treatments in keratinocyte tumours? 5- What about the psychosoc...

Expert: Berardino De Bari, Réseau Hospitalier Neuchâtelois, La Chaux-de-Fonds, Switzerland Questions: 1- Moderate hypofractionation is considered a standard of care in prostate radiotherapy. What is the state of the art in 2021 for extreme hypofractionation in prostate cancer? 2- What’s your point of view about the multidisciplinary approach to locally advanced prostate cancer? 3- Some very recent...

Expert: Oriana Ciani, Associate Professor of practice SDA Bocconi School of Management, Milan, Italy Questions: 1- What is a surrogate endpoint? 2- What are the advantages of using surrogate endpoints? 3- What are the pitfalls, instead? 4- How do we appropriately validate and apply surrogate-based evidence? 5- How do present surrogate measures in oncology measure up?

Expert: Nicola Rocco, University of Naples Federico II, Naples, Italy Questions: 1- What is Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)? 2- What is the clinical presentation of BIA-ALCL? 3- How can I diagnose BIA-ALCL? 4- How can I stage BIA-ALCL? 5- What is the treatment for BIA-ALCL?